Risk Evaluation and Mitigation Strategy program for FENTORA and ACTIQ
13 October 2011 | By Cephalon Inc
Healthcare professionals who prescribe & dispense FENTORA® & ACTIQ® can enroll in the REMS program...
List view / Grid view
13 October 2011 | By Cephalon Inc
Healthcare professionals who prescribe & dispense FENTORA® & ACTIQ® can enroll in the REMS program...
21 July 2011 | By Cephalon, Inc.
The FDA approved the Risk Evaluation and Mitigation Strategy for FENTORA® & ACTIQ®...
14 July 2011 | By Cephalon Inc.
Cephalon, Inc. announced that its stockholders voted to approve the TEVA proposal to acquire Cephalon...
20 May 2011 | By Cephalon Inc
The United States District Court for the District of Delaware granted a motion filed by plaintiffs Cephalon and Eurand for a TRO enjoining Mylan Pharmaceuticals and Mylan from manufacturing, using and selling its cyclobenzaprine hydrochloride extended-release capsules...
6 May 2011 | By Cephalon Inc
Cephalon, Inc. presented positive results from a phase IV trial...
2 May 2011 | By Cephalon, Inc.
Teva will acquire all of the outstanding shares of Cephalon for a total enterprise value of approximately $6.8 billion...